Days alive and out of hospital in patients with wild type transthyretin amyloidosis: cohort study

Abstract While overall survival has been extensively studied in amyloidosis, less attention has been given to patient-centered measures that integrate morbidity and mortality. Days Alive and Out of Hospital (DAOH) is an emerging metric that captures both aspects and has potential utility in the eval...

Full description

Saved in:
Bibliographic Details
Main Authors: Mariana Vaena, María Adela Aguirre, Teo Epstein, Agustín Schalum, Facundo Ezequiel Hilbert, María Lourdes Posadas-Martínez, Marcelina Carretero
Format: Article
Language:English
Published: Nature Portfolio 2025-08-01
Series:Scientific Reports
Subjects:
Online Access:https://doi.org/10.1038/s41598-025-14526-7
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849226347936743424
author Mariana Vaena
María Adela Aguirre
Teo Epstein
Agustín Schalum
Facundo Ezequiel Hilbert
María Lourdes Posadas-Martínez
Marcelina Carretero
author_facet Mariana Vaena
María Adela Aguirre
Teo Epstein
Agustín Schalum
Facundo Ezequiel Hilbert
María Lourdes Posadas-Martínez
Marcelina Carretero
author_sort Mariana Vaena
collection DOAJ
description Abstract While overall survival has been extensively studied in amyloidosis, less attention has been given to patient-centered measures that integrate morbidity and mortality. Days Alive and Out of Hospital (DAOH) is an emerging metric that captures both aspects and has potential utility in the evaluation of disease impact.To describe DAOH in patients with wild-type transthyretin amyloidosis (ATTRwt) and explore factors associated with DAOH.Retrospective cohort study used the Institutional Registry of Amyloidosis database of the Hospital Italiano de Buenos Aires (2015–2023). All patients with ATTRwt amyloidosis enrolled in the registry and affiliated with the health maintenance organization of the hospital were included. DAOH were estimated at 1, 3 and 5 years. Associations between DAOH and risk factors were evaluated.61 cases were included. The median age was 83 years, and 89% were male. Median (IQR) DAOH were 365 (353–365), 998 (553–1094) and 1314 (740–1769) days for 1, 3, and 5 years, respectively. Atrial fibrillation was associated with lower DAOH.DAOH is a simple, reproducible metric. Our findings highlight the importance of considering morbidity, not just mortality, in patients with ATTRwt amyloidosis.
format Article
id doaj-art-4ff21b9893df41e29eb6ee79a641b130
institution Kabale University
issn 2045-2322
language English
publishDate 2025-08-01
publisher Nature Portfolio
record_format Article
series Scientific Reports
spelling doaj-art-4ff21b9893df41e29eb6ee79a641b1302025-08-24T11:26:00ZengNature PortfolioScientific Reports2045-23222025-08-011511710.1038/s41598-025-14526-7Days alive and out of hospital in patients with wild type transthyretin amyloidosis: cohort studyMariana Vaena0María Adela Aguirre1Teo Epstein2Agustín Schalum3Facundo Ezequiel Hilbert4María Lourdes Posadas-Martínez5Marcelina Carretero6Internal Department Medicine, Hospital Italiano de Buenos AiresInternal Department Medicine, Hospital Italiano de Buenos AiresInternal Department Medicine, Hospital Italiano de Buenos AiresUniversity Hospital ItalianoUniversity Hospital ItalianoInstitute of Translational Medicine and Biomedical Engineering, CONICETInternal Medicine Research Unit, Internal Department Medicine, Hospital Italiano de Buenos AiresAbstract While overall survival has been extensively studied in amyloidosis, less attention has been given to patient-centered measures that integrate morbidity and mortality. Days Alive and Out of Hospital (DAOH) is an emerging metric that captures both aspects and has potential utility in the evaluation of disease impact.To describe DAOH in patients with wild-type transthyretin amyloidosis (ATTRwt) and explore factors associated with DAOH.Retrospective cohort study used the Institutional Registry of Amyloidosis database of the Hospital Italiano de Buenos Aires (2015–2023). All patients with ATTRwt amyloidosis enrolled in the registry and affiliated with the health maintenance organization of the hospital were included. DAOH were estimated at 1, 3 and 5 years. Associations between DAOH and risk factors were evaluated.61 cases were included. The median age was 83 years, and 89% were male. Median (IQR) DAOH were 365 (353–365), 998 (553–1094) and 1314 (740–1769) days for 1, 3, and 5 years, respectively. Atrial fibrillation was associated with lower DAOH.DAOH is a simple, reproducible metric. Our findings highlight the importance of considering morbidity, not just mortality, in patients with ATTRwt amyloidosis.https://doi.org/10.1038/s41598-025-14526-7Transthyretin proteinMortalityMorbidityPatient outcome assessmentValue-Based health care
spellingShingle Mariana Vaena
María Adela Aguirre
Teo Epstein
Agustín Schalum
Facundo Ezequiel Hilbert
María Lourdes Posadas-Martínez
Marcelina Carretero
Days alive and out of hospital in patients with wild type transthyretin amyloidosis: cohort study
Scientific Reports
Transthyretin protein
Mortality
Morbidity
Patient outcome assessment
Value-Based health care
title Days alive and out of hospital in patients with wild type transthyretin amyloidosis: cohort study
title_full Days alive and out of hospital in patients with wild type transthyretin amyloidosis: cohort study
title_fullStr Days alive and out of hospital in patients with wild type transthyretin amyloidosis: cohort study
title_full_unstemmed Days alive and out of hospital in patients with wild type transthyretin amyloidosis: cohort study
title_short Days alive and out of hospital in patients with wild type transthyretin amyloidosis: cohort study
title_sort days alive and out of hospital in patients with wild type transthyretin amyloidosis cohort study
topic Transthyretin protein
Mortality
Morbidity
Patient outcome assessment
Value-Based health care
url https://doi.org/10.1038/s41598-025-14526-7
work_keys_str_mv AT marianavaena daysaliveandoutofhospitalinpatientswithwildtypetransthyretinamyloidosiscohortstudy
AT mariaadelaaguirre daysaliveandoutofhospitalinpatientswithwildtypetransthyretinamyloidosiscohortstudy
AT teoepstein daysaliveandoutofhospitalinpatientswithwildtypetransthyretinamyloidosiscohortstudy
AT agustinschalum daysaliveandoutofhospitalinpatientswithwildtypetransthyretinamyloidosiscohortstudy
AT facundoezequielhilbert daysaliveandoutofhospitalinpatientswithwildtypetransthyretinamyloidosiscohortstudy
AT marialourdesposadasmartinez daysaliveandoutofhospitalinpatientswithwildtypetransthyretinamyloidosiscohortstudy
AT marcelinacarretero daysaliveandoutofhospitalinpatientswithwildtypetransthyretinamyloidosiscohortstudy